Autoimmunity and graves disease

R. S. Bahn

Research output: Contribution to journalReview article

29 Scopus citations

Abstract

Current treatment options for Graves hyperthyroidism and the related ophthalmopathy (GO) are not uniformly effective and carry with them potentially serious side effects. As a result, efforts have been focused on the development of novel therapies. Progress has been made, particularly in the production of thyroid-stimulating hormone receptor (TSHR) antagonists, as either monoclonal blocking antibodies or small-molecule ligands. In addition, rituximab (RTX) is the first targeted biological therapy to be studied as treatment for these conditions.

Original languageEnglish (US)
Pages (from-to)577-579
Number of pages3
JournalClinical pharmacology and therapeutics
Volume91
Issue number4
DOIs
StatePublished - Apr 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this